NEWTON, Mass.--(BUSINESS WIRE)--Matritech (Amex: MZT), a leading marketer and developer of protein-based diagnostic products for the early detection of cancer, today announced that it has filed a plan with the American Stock Exchange (AMEX) outlining the actions it proposes to take to bring it into compliance no later than March 21, 2008 with AMEX’s continued listing standards. Matritech previously announced that it had been informed that it was not in compliance with AMEX’s continued listing standards and was afforded the opportunity to submit a plan of compliance to the AMEX by October 23, 2006.
